Ibrutinib dose modifications in the management of CLL
Abstract Background Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally included in theclinical trials have additional unfavorable prognostic f...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2020-06-01
|
| シリーズ: | Journal of Hematology & Oncology |
| 主題: | |
| オンライン･アクセス: | http://link.springer.com/article/10.1186/s13045-020-00870-w |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|